IDH305

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

IDH1 inhibitor

Related drugs:

2ms

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations (clinicaltrials.gov)

P1, N=166, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2024 --> Oct 2025

2 months ago

Trial completion date • Metastases

IDH1 R132

IDH305

almost2years

Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis. (PubMed, Open Med (Wars))

However, current targeted inhibitors of IDH1 mutation (AG120 and IDH305) reversed these effects caused by IDH1 mutation. The in vivo experiment showed that IDH1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to erastin-induced ferroptosis. This study indicated that IDH1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to erastin-induced ferroptosis.

almost 2 years ago

Journal

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

IDH1 mutation • IDH1 R132C • IDH1 R132

Tibsovo (ivosidenib) • erastin • IDH305

2years

A phase 1 study of IDH305 in patients with IDH1-mutant acute myeloid leukemia or myelodysplastic syndrome. (PubMed, J Cancer Res Clin Oncol)

Due to potentially narrow therapeutic window, the study was prematurely halted and recommended phase 2 dose could not be declared.

2 years ago

P1 data • Journal

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

IDH1 mutation • IDH1 R132

IDH305